See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Health Care Videos on Diabetes Health TV

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Introducing Glucocil, a new Dietary Supplement that has shown promising results controlling post meal blood sugar levels.

Lee Zhong, M.D., Ph.D.

Introducing Glucocil, a new Dietary Supplement that has shown promising results controlling post meal blood sugar levels.

One of Our Advisory Board Members Wields a Mighty Pen

Jane Seley, GNP, MPH, MSN, CDE

One of Our Advisory Board Members Wields a Mighty Pen

Type 2

Page 2
Study Found Blood Sugar Levels Not Affected by Sucralose-sweetened Desserts
Aug 13, 2014 | 
While there has been much debate recently about the impact of artificial sweeteners on diabetes, a new study finds that desserts sweetened with sucralose don’t impact blood sugar levels.
Florida Nutrition Experts Seeing Higher Numbers of Type 2 in Children
Aug 12, 2014 | 
Three decades ago, type 2 diabetes wasn’t associated with children, but with middle-aged adults. In the 30 years that have passed since the advent of the Wendy’s “Where’s the Beef” ad campaign, the Teenage Mutant Ninja Turtles and Apple’s Mac computer, however, a lot has changed.
DHTV
Popular
Top Rated

Related Health Care Videos on Diabetes Health TV

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Introducing Glucocil, a new Dietary Supplement that has shown promising results controlling post meal blood sugar levels.

Lee Zhong, M.D., Ph.D.

Introducing Glucocil, a new Dietary Supplement that has shown promising results controlling post meal blood sugar levels.

One of Our Advisory Board Members Wields a Mighty Pen

Jane Seley, GNP, MPH, MSN, CDE

One of Our Advisory Board Members Wields a Mighty Pen

FDA Lifts Restrictions on Patient Access to Avandia
Aug 7, 2014 | 
The type 2-diabetes drug Avandia will again be available through retail pharmacies after a May ruling by the U.S. Food and Drug Administration.

The drug - a rosiglitazone-based medicine that controls blood glucose by increasing the body’s sensitivity to insulin, so cells and muscles are able to use more for energy, reducing levels in the blood - was off the market in Europe and restricted in the United States for several years due to studies showing the drug raised the risk of heart disease. The FDA in 2013 reversed its earlier opinion and lifted restrictions on the drug, opening the doors for Avandia’s return to market.

Initially released in 1999, Avandia had been one of Glaxo's top-selling medicines, with sales of $3.2 billion in 2006. Sales tanked in 2010 after a review of clinical trials showed an increased risk of heart attack related to the drug – those taking the drug in the United States dropped from 120,000 to 3,000 – but last year, new trials showed no elevated risk of heart attack or death in patients being treated with Avandia compared to other diabetes drugs, causing the FDA to reverse its opinion.

“GSK welcomes the decision of the FDA and appreciates the agency’s robust review of the science about Avandia,” Glaxo said in a statement last year. “GSK maintains its view that Avandia is a safe and effective treatment for Type 2 diabetes when used appropriately.”

While the drug had previously been available only through specialty pharmacies and the patients already taking the drug or whose symptoms were not adequately controlled by other drugs, the new FDA ruling allows all patient's access to Avandia, Avandamet and Avandaryl. All of these medications contain rosiglitazone.

“Our actions reflect the most current scientific knowledge about the risks and benefits of this drug,” Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a statement last year. “Given these new results, our level of concern is considerably reduced; thus, we require the removal of certain prescribing restrictions.”

While the drug’s manufacturer, GlaxoSmithKline, has a marketing hurdle to overcome given the bad press the drug has received over the last few years, the British drug maker has no plans to promote Avandia in the United States, in part because its U.S. patent protection lapsed in 2011.
The drug will be available by prescription.

To assist in the transition, a toll-free telephone number has been established for patients, healthcare professionals and pharmacies - 1-800-282-6342 – which will be staffed from 8;30 a.m. to 5 p.m. Monday through Friday Eastern Time.
Death Risk Higher in Polytrauma Cases for People With Diabetes
Aug 5, 2014 | 
Having diabetes increases the risk of complications or death in cases where patients have suffered polytrauma compared with patients who don't have any history of medical comorbidities. (Comorbidities are defined as the simultaneous presence of two chronic diseases in a patient.) Polytrauma is defined as multiple injuries to the body or organs where at least one is life-threatening and exacerbated by the trauma of the other injuries. Such injuries usually occur in situations where the likelihood of substantial injury is high---falls, auto accidents, violent crimes, industrial accidents.
Insulin pumps lead to lower A1C levels for insulin-dependent type 2s
Aug 2, 2014 | 
Insulin pumps can be as beneficial for those with type 2 diabetes that require insulin as they have become for those with type 1, according to a new trial.
USDA Announces $78 Million Available for Local Food Enterprises
Jul 28, 2014 | 
The local food movement was given a big boost earlier this month with the announcement that the USDA has plans to invest $78 million into local and regional food enterprises.
Novo Nordisk Introduces New Insulin Device to U.S. Market
Jul 26, 2014 | 
Novo Nordisk has introduced the Levemir® FlexTouch® prefilled insulin delivery device to the U.S. market. The device, filled with insulin detemir [rDNA origin], the first of its kind that does not use a pushbutton extension. In a conventional insulin delivery device, a pushbutton extends out from the device. If the called-for dose is large, an extension may cause problems for the user.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.